anastrozole / Generic mfg. - LARVOL DELTA

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning. (PubMed, Medicina (Kaunas)) - " Through an extensive review of the literature, our findings indicate that for premenopausal women with HR-positive, HER2-negative BC with a low risk of recurrence, standard 5-year monotherapy with tamoxifen represents the optimal therapeutic management, given its favorable clinical outcomes and lower associated toxicity...In postmenopausal patients with HR-positive, HER2-negative breast cancer with a low recurrence risk, the first line of treatment is usually a standard 5-year period of treatment with aromatase inhibitors (AIs)(letrozole, anastrozole, or exemestane). On the other hand, in postmenopausal women with an intermediate to high risk, combination therapy might be needed, as well as an extension of the standard therapeutic time. Treatment consensus depends on pre- vs. postmenopausal status and recurrence risk."

Journal • Review • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Bireociclib plus Letrozole/Anastrozole versus Placebo plus Letrozole/Anastrozole for the Treatment of HR+/HER2- Advanced Breast Cancer: Interim Analysis of BRIGHT-3 study (ESMO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Comparative Effectiveness of Anastrozole, Letrozole, and Exemestane as adjuvant endocrine therapy in Postmenopausal Early-Stage Hormone-Receptor Positive Breast Cancer: A Nationwide Cohort Study (ESMO 2025) - No abstract available

Clinical • HEOR • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

TACTIVE-N: phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC) (ESMO 2025) - No abstract available

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CDK4

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Jul 2031 ➔ Jul 2032 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole (clinicaltrials.gov) - P=N/A | N=16989 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • Breast Cancer • CNS Disorders • Oncology • Solid Tumor

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

In Vitro Metabolism of Doping Agents (Stanozolol, LGD-4033, Anastrozole, GW1516, Trimetazidine) by Human Seminal Vesicle and Liver Fractions. (PubMed, Metabolites) - "Gene expression and enzymatic activity in CYP3A4 and CYP1A2-major hepatic enzymes-were absent in SV-S9. Overall, these pilot study results suggest that the seminal vesicle has only a low capacity for xenobiotic metabolism, which translates into a limited role in the biotransformation of drugs and, hence, the metabolic pattern."

Journal • Preclinical • CYP1A2 • CYP2C9 • CYP2E1 • CYP3A4

Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention. (PubMed, JAMA Oncol) - "Undergoing RRM or receiving risk-stratified BC screening with medical prevention (tamoxifen or anastrozole). These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted."

Journal • Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • PALB2

Multidisciplinary approach for a patient with morbid obesity and psychological issues led from the pharmacy office (PubMed, Farm Comunitarios) - "Take metformin, rosuvastatin, and anastrozole...In the emergency department, he undergoes an ultrasound and intravenous analgesics that relieve the pain, diagnoses nephritic colic and prescribes metamizole and tramadol/paracetamol...The pharmacist makes a second referral to the doctor, with a written communication of suspicion of Herpes Zoster, the doctor accepts the intervention and changes the treatment by putting Valacyclovir, paracetamol/codeine and capsaicin cream. The patient returns to the pharmacy reporting that the doctor was surprised that it was a pharmacist who gave the correct diagnosis."

Journal • Breast Cancer • Diabetes • Dyslipidemia • Genetic Disorders • Herpes Zoster • Metabolic Disorders • Obesity • Oncology • Pain • Solid Tumor • Varicella Zoster

Breast carcinoma in a patient with neurofibromatosis type 1 and huge plexiform neurofibroma of the contralateral breast: a case report. (PubMed, BMC Womens Health) - "It is known that women with NF1 have a higher risk of developing breast cancer, as demonstrated in our case. These patients could benefit from an early start of breast cancer screening, which could lead to an early diagnosis of early-stage tumors and a better prognosis. Additionally, enhanced access to healthcare centers and intensive surveillance could contribute significantly to better outcomes."

Journal • Breast Cancer • Genetic Disorders • Musculoskeletal Pain • Neurofibromatosis • Oncology • Pain • Solid Tumor • NF1

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) - P1/2 | N=44 | Active, not recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

TRIO-US B-12 TALENT: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - P2 | N=88 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

Brain Blood Flow Responses to Stress: Sex Differences (clinicaltrials.gov) - P4 | N=22 | Completed | Sponsor: University of Wisconsin, Madison | Recruiting ➔ Completed | Trial completion date: Jul 2026 ➔ May 2025

Trial completion • Trial completion date • CNS Disorders • Vascular Neurology

A Rare Case of Metastasis of Renal Cell Carcinoma to Thyroid Gland presenting as Neck Mass, Four Years After Nephrectomy. (ENDO 2025) - "Her cancer history also included right breast ductal carcinoma in situ (DCIS), diagnosed in 2011, and left breast invasive ductal carcinoma (IDC) in 2019, for which she underwent lumpectomy and currently on anastrozole.The patient had been disease-free post-surgery with routine follow-up, including CT scans and renal ultrasounds, whit no signs of recurrence...These findings further supported the diagnosis of thyroid metastasis from RCC.This case underscores the importance of ongoing surveillance in RCC survivors, even many years after initial treatment, as metastasis can occur long after the primary disease is considered "disease-free." Thyroid metastasis from RCC, while rare, should be considered in the differential diagnosis of thyroid nodules in patients with a history of RCC, mainly when unusual presentation patterns occur. This case contributes to understanding RCC metastasis to the thyroid, emphasizing the need for vigilance in follow-up care and..."

Clinical • Breast Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • BRAF • CA9 • MME • NKX2-1 • PAX8

A Case of Anastrozole Induced Hyperandrogenism (ENDO 2025) - "Patient was switched from anastrozole to exemestane by her oncologist and was started on spironolactone for persisting hirsutism and scalp hair thinning. Anastrozole as a cause of hirsutism or hyperandrogenism has not been commonly described and may be considered after exclusion of more serious causes."

Clinical • Acne Vulgaris • Alopecia • Breast Cancer • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Leydig Cell Tumor: A Rare Cause of Hyperandrogenism (ENDO 2025) - "Anastrozole was suspected to be the cause of her hyperandrogenism, so it was replaced with Tamoxifen. Sudden hyperandrogenism in postmenopausal women warrants investigation for hormonally active ovarian tumors. These tumors, though distressing, are curable with surgery. Long-term follow-up is essential to monitor for recurrence or metastasis, even in benign cases."

Acromegaly • Alopecia • Breast Cancer • Endocrine Disorders • Gynecology • Oncology • Ovarian Cancer • Polycystic Ovary Syndrome • Solid Tumor

Ovarian Stromal Hyperplasia: A Rare Cause of Hyperandrogenism in a 59-Year-Old Female With Treatment Related Menopause and Normal Imaging Findings (ENDO 2025) - "Her treatment for TNBC involved neoadjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel, anastrozole, and Xeloda which resulted in treatment related menopause...Because of the normal imaging findings, a 3-day dexamethasone suppression test was completed, which resulted in persistently elevated Testosterone levels... We present a rare case of hyperandrogenism that was found to be secondary to OSH and resulted in biochemical resolution after surgical intervention. The diagnosis of OSH is difficult but important to consider when the clinical suspicion is high."

Stroma • Alopecia • Breast Cancer • Gynecology • Oncology • Rare Diseases • Solid Tumor • Triple Negative Breast Cancer

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Antioxidant, antimicrobial and in silico investigations on pyrolytic bio-oil from invasive Stachytarpheta jamaicensis. (PubMed, Environ Sci Pollut Res Int) - "Molecular docking studies further identified key bioactive ligands including 3,5-dimethoxy-4-hydroxytoluene and phenol, 2-methoxy- that mirrored notable binding affinities to well-established breast cancer therapeutics such as anastrozole and letrozole. The integration of appropriate bioresource utilization, bioactive profiling and bio-oil application strongly affirmed the potential for therapeutic breakthroughs and futuristic drug discovery from repurposed invasive species biomass."

Journal • Breast Cancer • Oncology • Solid Tumor

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=474 | Not yet recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P3 trial • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov) - P2 | N=83 | Active, not recruiting | Sponsor: Shayna Showalter, MD | Trial completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Update in the clinical utilization of chemoprevention for breast cancer: a narrative review. (PubMed, Front Oncol) - "Raloxifene, another SERM, has risk-reducing benefits with a better safety profile compared to tamoxifen. AI, like anastrozole and exemestane, reduced invasive breast cancer with better side effect profile. Denosumab, a monoclonal antibody that tackles receptor activator of nuclear factor kappa B (RANK-RANKL), is promising in preventing breast cancer in healthy carriers of pathogenic BRCA1 variants...However, careful consideration of side effects and individual risk factors are crucial to enhance uptake rate. Further research is needed to compare the effectiveness of SERMs and AI in preventing breast cancer, especially in high-risk populations with pathogenic germline mutations."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • BRCA1 • TNFRSF11A

Important negative trials in pulmonary hypertension. (PubMed, Curr Opin Pulm Med) - "This article provides an overview of the key learning points from these studies and reinforces the importance of the publication of all trials, irrespective of outcome, so that we can learn from negative studies and prioritize promising therapies and treatment pathways."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases